文献速递其他结缔组织病

Sema4A中和抗体减轻系统性硬化症小鼠模型及三维免疫驱动纤维化模型的纤维化和炎症

Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity-driven fibrosis.
PubMed 文献 · Arthritis Rheumatol · 2026-10-20

该研究在系统性硬化症(SSc)患者血浆中确认Sema4A升高,并在博来霉素诱导的SSc小鼠模型及三维纤维化模型中验证Sema4A中和的抗纤维化与抗炎作用。抗Sema4A治疗显著降低小鼠皮肤和肺胶原含量及纤维化、炎症介质表达,并减轻免疫细胞浸润。三维模型中阻断Sema4A可显著消除SSc血清和PBMC诱导的细胞收缩,伴随纤维化介质表达下降和mTORC1通路活化减弱。

要点

  • SSc患者循环Sema4A水平显著升高,其受体在SSc皮肤和肺中表达上调。
  • 抗Sema4A抗体显著减少博来霉素小鼠皮肤和肺胶原含量及纤维化、炎症介质表达。
  • 三维模型中阻断Sema4A显著消除SSc血清和PBMC诱导的细胞收缩及mTORC1活化。

核心结论

  • Sema4A具有促纤维化和促炎作用,中和Sema4A可能是治疗SSc的新策略。

研究设计与样本

  • ELISA检测健康对照(n=31)和SSc患者(n=30)血浆Sema4A水平。
  • 博来霉素SSc小鼠模型接受抗Sema4A中和抗体或同型对照(n=6-7)。
  • 三维纤维化模型由胶原水凝胶、真皮成纤维细胞和外周血单核细胞构成,给予重组Sema4A、雷帕霉素或中和Sema4A、PlexinD1、PlexinB2、Neuropilin-1的抗体或同型对照(n=6-10)。

主要发现

  • SSc患者循环Sema4A升高(p<0.0001),Sema4A受体在SSc皮肤和肺中升高(p范围<0.05至0.0001)。
  • 抗Sema4A给药显著降低博来霉素处理小鼠皮肤和肺胶原含量(p<0.01),并减少细胞外基质成分、纤维化和炎症介质表达及免疫细胞浸润。
  • 三维模型中SSc血清和SSc PBMC诱导细胞收缩,阻断Sema4A后该效应显著减弱(p<0.01),伴随纤维化介质表达下降和mTORC1通路活化减弱。

临床怎么用

  • Sema4A及其受体可作为SSc纤维化和炎症的潜在生物标志物与治疗靶点。
  • 抗Sema4A中和策略在动物模型和三维模型中显示抗纤维化与抗炎效果,支持进一步临床转化研究。

局限性

  • 研究为小鼠模型和体外三维模型,尚需临床研究验证Sema4A中和在SSc患者中的安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: OBJECTIVE: We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. METHODS: Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=30). In the bleomycin SSc-model, mice were treated with an anti-Sema4A neutralizing antibody or its respective isotype control (n=6-7). The 3D fibrosis models, consisting of collagen hydrogel, dermal fibroblasts, and peripheral blood mononuclear cells, were stimulated with recombinant Sema4A, rapamycin, or antibodies neutralizing Sema4A, PlexinD1, PlexinB2, Neuropilin-1 or their respective isotype controls (n=6-10). Collagen content was determined by trichrome staining and hydroxyproline assay. Gene expression was determined by RT-qPCR and obtained from GEO-NCBI expression arrays, while protein expression by immunohistochemistry, immunoblotting and flow cytometry. RESULTS: Circulating Sema4A was elevated in patients with SSc (p<0.0001), while Sema4A receptors were elevated in SSc skin and lung (p ranged from <0.05 to 0.0001). Anti-Sema4A administration significantly reduced skin and lung collagen content in bleomycin-treated mice (p<0.01), as well as the expression of extracellular matrix components, fibrotic and inflammatory mediators, and immune cell infiltration. In the 3D models, SSc serum and SSc PBMCs induced cell contraction, which was drastically abrogated by blocking Sema4A (p<0.01). This effect was associated with reduced expression of fibrotic mediators and attenuated mTORC1 pathway activation. CONCLUSIONS: We confirmed the pro-fibrotic and pro-inflammatory role of Sema4A, postulating Sema4A neutralization as a novel approach for the treatment of SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Marty J, Martinez-Ramos S, Rafael-Vidal C, et al. Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity-driven fibrosis. Arthritis Rheumatol. 2026. PMID: 42901728. doi:10.1002/art.70374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。